Table 2 Characteristics of the patients with vs. without bleeds
Rivaroxaban 20 | Rivaroxaban 15 | |||||
|---|---|---|---|---|---|---|
Without bleeding N = 17 | With bleeding N = 13 | p-value | Without bleeding N = 15 | With bleeding N = 15 | p-value | |
Age (years) | 69 (59–78) | 73 (61–80) | 0.516 | 77 (64–87) | 76 (63–83) | 0.130 |
Gender, female/male | 3/14 | 6/7 | 0.123 | 10/5 | 9/6 | 1.000 |
Body weight (kg) | 90 (60–112) | 89 (64–140) | 0.064 | 73 (60–102) | 84 (66–134) | 0.909 |
Hypertension, N (%) | 15 (88) | 11 (85) | 1.000 | 15 (100) | 13 (87) | 0.483 |
Diabetes, N (%) | 1 (6) | 3 (23) | 0.290 | 5 (33) | 4 (27) | 1.000 |
Chronic heart failure, N (%) | 4 (24) | 2 (15) | 0.672 | 5 (33) | 3 (20) | 0.682 |
Peripheral Artery Obstructive Disease, N (%) | 1 (6) | 0 | 1.000 | 1 (7) | 0 | 1.000 |
Ischemic Heart Disease, N (%) | 4 (24) | 2 (15) | 0.672 | 3 (20) | 3 (20) | 1.000 |
Cerebrovascular Insult, N (%) | 2 (12) | 1 (8) | 1.000 | 2 (13) | 3 (20) | 1.000 |
CHA2DS2VASc score | 1.6 +/-1.2 | 2.0 +/-1.4 | 0.668 | 2.7 +/-1.2 | 2.3 +/-1.1 | 0.845 |
HAS-BLED Score | 0.8 +/-0.7 | 1.1 +/-0.6 | 0.096 | 1.3 +/-0.5 | 1.2 +/-0.6 | 0.592 |
No. of bleeding events | ||||||
1 2 3 4 | 0 0 0 0 | 9 2 1 1 | 0 0 0 0 | 6 6 1 2 | ||